Upgrade to SI Premium - Free Trial

Acadia (ACAD) PT Lifted to $26 at Needham & Company

August 7, 2013 8:52 AM
Needham & Company analyst Alan Carr boosted his price target on Buy-rated Acadia Pharmaceuticals (NASDAQ: ACAD) from $16 to $26 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst EPS View Analyst PT Change

Next Articles